Kyle A. Robinson

Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines

Christopher S. Burgey, Kyle A. Robinson, Terry A. Lyle et al. · Journal of Medicinal Chemistry · 2003 · 120 citations · Full text

Pharmaceutical Science, Oral Bioavailability, Pharmacotherapy +18

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. implementation of P3 pyridine N-Oxides to deliver an orally bioavailable series containing P1 N-Benzylamides

Christopher S. Burgey, Kyle A. Robinson, Terry A. Lyle et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 38 citations · Full text

P1 N-benzylamides, Pharmaceutical Science, Pharmacokinetic Modeling +10

P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold

Philippe G. Nantermet, Christopher S. Burgey, Kyle A. Robinson et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 21 citations · Full text

Thrombosis, Medicinal Chemistry, Novel Peptidomimetic Scaffold +8